company background image
PHIO logo

Phio Pharmaceuticals NasdaqCM:PHIO Stock Report

Last Price


Market Cap







16 Apr, 2024


Company Financials +

Phio Pharmaceuticals Corp.

NasdaqCM:PHIO Stock Report

Market Cap: US$3.1m

PHIO Stock Overview

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.

PHIO fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

Phio Pharmaceuticals Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Phio Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.65
52 Week HighUS$12.27
52 Week LowUS$0.50
1 Month Change-31.06%
3 Month Change3.68%
1 Year Change-86.68%
3 Year Change-97.49%
5 Year Change-99.80%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Phio Pharmaceuticals appoints interim executive chairman

Sep 29

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Aug 11

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Nov 09

Shareholder Returns

PHIOUS BiotechsUS Market

Return vs Industry: PHIO underperformed the US Biotechs industry which returned -1.8% over the past year.

Return vs Market: PHIO underperformed the US Market which returned 20.9% over the past year.

Price Volatility

Is PHIO's price volatile compared to industry and market?
PHIO volatility
PHIO Average Weekly Movement14.8%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: PHIO's share price has been volatile over the past 3 months.

Volatility Over Time: PHIO's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of US stocks.

About the Company


Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.

Phio Pharmaceuticals Corp. Fundamentals Summary

How do Phio Pharmaceuticals's earnings and revenue compare to its market cap?
PHIO fundamental statistics
Market capUS$3.06m
Earnings (TTM)-US$10.83m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHIO income statement (TTM)
Cost of RevenueUS$6.33m
Gross Profit-US$6.33m
Other ExpensesUS$4.49m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date


Earnings per share (EPS)-2.36
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PHIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.